London: Vaccine development is in full swing in the corona worldwide. Many companies have developed vaccines and many companies are engaged in making them. At the same time, a two-dose vaccine against the Ebola virus, invented by the American drugmaker Johnson & Johnson, is safe and creates a strong immunity in people older than one year, according to two new infectious disease research papers published in the Lancet. Studies have provided significant evidence for the potential for survival using the A-26 Ebola vaccine and the MVA-BN-Philo vaccine, which are used as a protective measure against the Ebola virus for both children and adults.
Researchers at the London School of Hygiene and Tropical Medicine (LSHTM) and the Sierra Leone College of Medicine and Allied Health Sciences (COMAHS) found that the vaccine method was well tolerated and that one percent of participants received the drug 21 days after the second day. Dosage. Antibodies to the Ebola virus maintain immunity in at least two years of age.
During 2014-16, an Ebola outbreak, 28,652 cases and 11,325 Ebola deaths were reported in West Africa. In about 20 percent of cases, children under the age of 15 have a higher risk of death than children under the age of five.
LSHTM Assistant Professor Dr.
“The results show that this vaccine has the potential to save the lives of many young people,” he said.
For the clinical trial, divided into two phases, the team recruited participants from September 2015 to July 2018. In the first phase, which aimed to gain preliminary information about the safety and immunogenicity of the vaccine, 43 adults 18 years of age or older received the MVA-BN-filo vaccine 56 days after the A26 Ebola vaccine.
In the second phase, 400 adults and 576 children and adolescents (192 in each of the three ages 1-3, 4-11 and 12-17 years) were vaccinated with the Ebola vaccine method (A26 Ebola vaccine). . MVA-BN-filo) or placebo at 57 days after a single dose of meningococcal quadruple vaccine.
Adults who took part in the first phase of the study were given a booster dose of the A26 Ebola vaccine two years after the first dose, which showed strong immunity within seven days.